Ilomedin (Iloprost Trometamol)

Ilomedin (iloprost trometamol) is a prostacyclin analog employed in the management of pulmonary vascular disorders and related peripheral vascular conditions, where vasodilation and platelet inhibition are therapeutic goals.

• Pulmonary arterial hypertension: improves exercise capacity and reduces pulmonary arterial pressure.
• Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation.
• Peripheral arterial disease: alleviates limb ischemia and reduces risk of critical limb ischemia.
• Prevention of vasospasm in surgical settings: helps maintain vessel patency during procedures.
• Chronic thromboembolic pulmonary hypertension: supports hemodynamic improvement when other therapies are insufficient.

• Iloprost trometamol is a synthetic analogue of prostacyclin (PGI2) that binds to the IP (prostacyclin) receptor on vascular smooth‑muscle cells and platelets. Receptor activation stimulates adenylate cyclase, increasing intracellular cyclic‑AMP, which leads to relaxation of smooth muscle, vasodilation, and inhibition of platelet aggregation. These actions collectively improve oxygen delivery to tissues and mitigate vascular remodeling.

Ilomedin may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Flushing: transient warmth and redness of the skin, usually brief.
• Headache: mild to moderate intensity, often responsive to analgesics.
• Nausea: occasional upset stomach that may resolve without treatment.
• Diarrhea: loose stools that are generally self‑limiting.
• Jaw pain: discomfort during chewing, reported by some patients.
• Hypotension: mild drop in blood pressure, typically asymptomatic.

Serious or Rare Side Effects

• Severe hypotension: marked blood pressure fall that may require medical intervention.
• Pulmonary edema: accumulation of fluid in the lungs leading to breathing difficulty.
• Bleeding complications: excessive or uncontrolled bleeding, including gastrointestinal hemorrhage.
• Thrombocytopenia: low platelet count that can increase bleeding risk.
• Allergic reactions: rash, itching, or anaphylaxis requiring immediate care.

When using Ilomedin, several precautionary measures should be observed to ensure patient safety and product integrity.

• Contraindication: avoid use in patients with known hypersensitivity to iloprost or its excipients.
• Monitoring: observe blood pressure and heart rate during infusion, adjusting rate as needed.
• Pregnancy: use only if potential benefit justifies potential risk, as safety data are limited.
• Breastfeeding: discontinue if adverse effects are observed in the infant; data are insufficient.
• Drug interactions: assess concomitant use of anticoagulants or other vasodilators for additive effects.
• Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ilomedin can interact with other medicines; awareness of significant and moderate interactions helps optimize therapy.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin, heparin): concurrent use can markedly increase bleeding risk and require close coagulation monitoring.
• Other prostacyclin analogues: combined therapy may cause excessive vasodilation and severe hypotension.

Moderate Interactions (Monitor Closely)

• Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may enhance vasodilatory response, necessitating blood pressure observation.
• Calcium channel blockers: additive effect on vascular smooth‑muscle relaxation may lower blood pressure.
• Non‑steroidal anti‑inflammatory drugs: can interfere with platelet inhibition, altering bleeding tendency.
• Beta‑blockers: may blunt compensatory tachycardia during hypotensive episodes.